• BioLineRx posted a net loss of USD 2.6 million in Q1 2026, swinging from net income of USD 5.1 million a year earlier.
• Revenue rose 66.67% to USD 0.5 million, on higher APHEXDA royalties; APHEXDA Q1 sales were USD 2.7 million.
• R&D expenses climbed 55.8% to USD 2.5 million, driven primarily by spending on the GLIX1 program.
• Cash, cash equivalents and short-term bank deposits totaled USD 17.4 million at March 31; cash runway guidance maintained into H1 2027.
• First patient dosed in the Phase 1/2a GLIX1 glioblastoma trial; new preclinical data showed anti-tumor effects, including in TMZ-resistant models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLineRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270700PR_NEWS_USPR_____LN67765) on May 27, 2026, and is solely responsible for the information contained therein.